The federal government has agreed to purchase at least 100,000 doses of the combination monoclonal antibody therapy bamlanivimab and etesevimab, Eli Lilly and Company announced Friday.

The Food and Drug Administration last month issued an emergency use authorization to administer the antibodies together to patients with mild-to-moderate COVID-19 at high risk for progressing to severe disease but not hospitalized or on oxygen therapy.

Related News Articles

Headline
The monoclonal antibody therapy REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic COVID-19 in household contacts of people with SARS-CoV-2…
Headline
The Food and Drug Administration and Centers for Disease Control and Prevention today jointly recommended a pause in the use of Johnson & Johnson’s…
Headline
Pfizer today said it is seeking an amended emergency use authorization for its COVID-19 vaccine, requesting that the Food and Drug Administration allow…
Headline
Nearly 80% of prekindergarten through 12th grade teachers, school staff and child care workers had received at least their first COVID-19 shot by April, the…
Headline
Leaders from Henry Ford Health System and the Islamic Center of America discuss their collaboration to increase vaccinations in the Muslim community around…
Headline
The Moderna COVID-19 vaccine continued to protect 33 healthy adults six months after receiving the second dose, according to an ongoing clinical trial…